A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

This study is testing a new drug called MRG007 (also called ARR-217) — an antibody-drug conjugate that targets a protein called CDH17 found on certain cancer cells — in people with advanced solid tumors that have not responded to standard treatments. **You may be eligible if...** - You have been diagnosed with an advanced or metastatic solid tumor that failed standard treatment options - Your tumor has been tested (or you agree to a biopsy) for CDH17, the protein the drug targets - You have at least one measurable tumor on imaging - You are in good to fair physical condition - Your liver, kidneys, and blood counts are in acceptable range **You may NOT be eligible if...** - You have more than one type of cancer - You have previously received a CDH17-targeting therapy - You have active hepatitis B or C, or HIV infection - You have significant heart or lung disease - You have uncontrolled fluid buildup around your heart, lungs, or abdomen Talk to your doctor to see if this trial is right for you.